Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.82 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181480 | 0.91 | KCNH2 (1.00) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181631 | 0.90 | HDAC2 (1.00) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181663 | 0.90 | HDAC2 (1.00) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181500 | 0.88 | HDAC2 (0.84) | KCNH2HDAC2HDAC3HDAC1CYP1A2 | |
| SCHEMBL20181692 | 0.87 | HDAC2 (1.00) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181513 | 0.87 | HDAC2 (1.00) | KCNH2HDAC2HDAC3HDAC1CYP1A2 | |
| SCHEMBL20181478 | 0.86 | HDAC2 (0.67) | KCNH2HDAC2HDAC3HDAC1CYP1A2 | |
| SCHEMBL20181476 | 0.86 | HDAC2 (0.80) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181470 | 0.86 | HDAC2 (1.00) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181530 | 0.86 | HDAC2 (1.00) | KCNH2HDAC2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | KCNH2 3509/4885HDAC2 2/4885HDAC3 7/4885 |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | KCNH2 3232/4885HDAC2 2/4885HDAC3 8/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 4371/4885HDAC2 2/4885HDAC3 6/4885 |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | KCNH2 3225/4885HDAC2 2/4885HDAC3 7/4885 |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 3551/4885HDAC2 2/4885HDAC3 7/4885 |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 4371/4885HDAC2 2/4885HDAC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.